E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients over 75 years with acute coronary syndrome |
Pazienti over 75 con sindrome coronarica acuta |
|
E.1.1.1 | Medical condition in easily understood language |
Patients over 75 with acute myocardial infarction and unstable angina |
Pazienti over 75 con infarto miocardico acuto e con angina instabile |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10051592 |
E.1.2 | Term | Acute coronary syndrome |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10071111 |
E.1.2 | Term | Non ST segment elevation acute coronary syndrome |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary aim will be to investigate the antiplatelet effect of half dose of prasugrel (5 mg) versus standard dose of clopidogrel in patients with acute coronary syndrome and coronary diseases, treated with percutaneous coronary intervention and stent implantation. |
Lo scopo dello studio è quello di confrontare gli effetti farmacodinamici della standard dose di clopidogrel vs la dose ridotta di prasugrel in pazienti con sindrome coronarica acuta e responder alla terapia standard con clopidogrel |
|
E.2.2 | Secondary objectives of the trial |
We will assess the different variability in terms of therapeutic window maintenance between the two drugs. Bleeding (major, minor, or minimal according to the TIMI study criteria) and major adverse cardiac events (cardiovascular death, myocardial infarction, and stroke) will be evaluated during the all period of treatment. |
Abbiamo intenzione di controllare la variabilità in termini di mantenimento della finestra terapeutica tra i due farmaci. I sangiunamenti (criterio TIMI) e gli eventi avversi cardiaci maggiori (morte cardiovascolare, infarto miocardico e stroke) saranno valutati durante tutto il periodo di trattamento. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Pazients over 75 years with acute coronary syndrome (unstable angina, NSTEMI and STEMI) undergoing percutanous coronary angioplasty and responder to clopidogrel therapy. |
Pazienti con più di 75 anni e con sindrome coronarica acuta (angina instabile, infarto STEMI e NSTEMI) sottoposti ad impianto di stent coronarico e risultanti responder alla terapia con clopidogrel. |
|
E.4 | Principal exclusion criteria |
Pazients under 75 year and patients without acute coronary syndrome |
Pazienti con meno di 75 anni e che non presentano una sindrome coronarica acuta |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary end-point of the study is to demonstrate the superiority antiplatelet effect of half dose of prasugrel compared to standard dose of clopidogrel into therapeutic window, at the study periods. |
L'end point primario dello studio è di dimostrare la superiorità di effetto della mezza dose di prasugrel paragonata al clopidogrel nella finestra terapeutica durante il periodo dello studio |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The timepoint of evaluation of this study is 1 month. |
L'end point primario verrà valutato dopo un mese. |
|
E.5.2 | Secondary end point(s) |
Secondary end-points included the rate MACCE (major adverse cerebro-cardiovascular events, i.e. the composite of death, myocardial infarction [defined according to the Academic Research Consortium statement],(17) target vessel revascularization or stroke), major bleedings (Bleeding Academic Consortium [BARC] 3-5),(18) minor bleeding (BARC 2), and NACE (net adverse clinical events, i.e. the composite of MACCE and major bleedings) up to 12 months |
L'end point secondario include la percentuale di MACCE (morte, infarto miocardico, rivascolarizzazione del vaso target) sanguinamenti maggiori, sanguinamenti minori e NACE (insieme di MACCE e sanguinamenti maggiori) ad un anno. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
telephone-based interviews and office-based direct visits will be performed at 7-14-21 and 28 days and 12 months, respectively, for end-point adjudication. |
Telefonate di intervista e visite dirette saranno effettuate a 7-14-21 e 28 giorni e a 12 mesi per la verifica degli end points. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
1 year 6 months |
1 anno 6 mesi |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 14 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 2 |